Pharmacy chains activity analysis

Pharmacy chains activity analysis

Russian pharmaceuticals retail chain segment evaluation, both on the level of the state and in particular regions. Pharmacy chains development forecast

Forecasting

Product sales and separate market development forecast, based on unique mathematical models

Business and marketing plan development

Development of detailed business-plans, required to evaluate the reasonability of project start

Search of partners for contract production in Russia

Potential partners search and evaluation, based on their technical opportunities, appropriate experience, and reputation

Monitoring of import substitution

assessment of the main trends of import substitution policies and localization processes in the pharmaceutical market in Russia, the key beneficiaries and companies at risk

News, archive: April 2023

4/27/2023 Pharmaceutical Drug Production in Russia (March and Q1 2023)

In Q1 2023, Russian manufactures produced 167.6 billion rubles’ worth of ready-made pharmaceutical drugs (manufacturer’s prices, VAT included), down 9.8% from Q1 2022. In physical terms, the production was 0.98 billion packages, down 10.3% from Q1 2022. If calculated in minimum dosage units (MDU), the production went down 3.9%, with 19.1 billion MDUs.

4/13/2023 Study by RNC Pharma and Medvestnik: 70% of Russian Doctors Want to Leave Public Healthcare Due to Low Salaries and Overwork, 30% Would Leave if Offered Decent Alternatives

39.6% of physicians think they could leave public healthcare in favor of a private medical institution due to “unjustifiably low salaries”, according to a survey conducted by the RNC Pharma analyst company and the Medvestnik platform for doctors. Another popular reason is “excessive workload and constant overwork”, voted by 31.3% of the respondents.

4/10/2023 Study by RNC Pharma and Medvestnik: 72% of Russian Doctors Want to Retrain, 21% Actually Plan to

While most Russian physicians would like to be able to have additional training in a narrower specialty, the options offered by the Ministry of Health are not suitable for 28.9%, according to a survey conducted by the RNC Pharma analyst company and the Medvestnik platform for doctors.